Psychology Today | 22.06.2026 22:28
New glucagon-like peptide-1 (GLP‑1) weight‑management medications such as Mounjaro and Wegovy represent a major shift in obesity treatment. In the United States, recent survey data suggest that about one in eight adults has taken a GLP‑1 medication, and around 6 percent are currently using one.[1] In the United Kingdom, it is estimated that nearly one in 10 adults have either recently used or are actively interested in these drugs.[2]
